Abstract:Abstract Background One of the most feared complications of endoscopic retrograde cholangiopancreatography (ERCP), with an incidence of 3.5 to 15%, is post ERCP pancreatitis (PEP). Given the role of statins in the reduction of systemic and pancreatic intraluminal inflammation, we hypothesized that the use of statins may lower the risk of PEP. Methods A retrospective cohort study of all patients undergoing ERCP at West Virginia University during the years 2016 and 2017 was performed. Possible association of collected variables with PEP was assessed with Univariate tests and multivariable logistic regression analyses. Results A total of 1162 ERCPs were included. Mean age was 60.12 years (SD: 17.5). 51.3% of the participants were female. Two hundred and sixty-three participants underwent more than one ERCP during the study period. Seven hundred and ninety-nine ERCPs (78.8%) were conducted in participants who were not taking a statin medication at the time of ERCP, while 363 participants were on statin medications at the time of ERCP; 118 and 245 participants were taking high dose statins (atorvastatin 40–80 mg or rosuvastatin 20 mg), and low/medium dose statins (all other statin regimens) at the time of the procedure, respectively. The overall incidence of PEP in the cohort was 7.3%. In the non-statin and statin groups, 9.5 and 3.4% of participants developed PEP, respectively. On univariate analysis, young age, no statin use, history of PEP, and endoscopic sphincterotomy were found to be significantly associated with the development of PEP. In a binary logistic regression model, young age ( P = 0.033), history of PEP ( P = 0.0001, OR 2.41, 95% CI: 1.05–5.51) and endoscopic sphincterotomy ( P = 0.038, OR 2.85, 95% CI: 1.7–4.78) were found to be associated with increased risk of PEP. Statin usage was found to be protective against PEP, (OR 0.35, 95% CI: 0.18–0.69). Conclusion Chronic statin usage is protective against post ERCP pancreatitis, and our findings suggest a potential role of these drugs as prophylactic agents. Randomized controlled trials are needed to establish any potential clinical application.

S1623 Impact of Statin Use on Post-ERCP Complications: A U.S. Cohort Propensity-Matched Study

Reduced risk of post ERCP pancreatitis in statin users

The Effect and Underlying Mechanism of Statins in the Prevention of Post-Contrast Acute Kidney Injury: A Multicenter Retrospective Observational Study

S2036 Association Between Statin Use and Clinical Outcomes in Patients With Primary Sclerosing Cholangitis and Inflammatory Bowel Disease: A Propensity Score-Matched Analysis

S1607 Assessing the Risk of Post-ERCP Pancreatitis and other ERCP Complications Among Patients Given Prophylactic Oral Tacrolimus

Comparative Risks of Post-ERCP Adverse Events in Patients with Asymptomatic and Symptomatic Choledocholithiasis: A Systematic Review and Meta-Analysis

Prevention of post-ERCP complications

Timing of Endoscopic Retrograde Cholangiopancreatography in Postcholecystectomy Patients and Its Effect on Post-ERCP Complications

Comparative effectiveness of pharmacologic and endoscopic interventions for prevention of post-ERCP pancreatitis: a network meta-analysis

Magnesium Sulfate for Prevention of Post-ERCP-Pancreatitis: A Randomized Controlled Trial

Technical factors associated with the benefit of prophylactic pancreatic stent placement during high-risk ERCP: a secondary analysis of the SVI trial dataset

S1584 Predictors of Inpatient Hospital Pancreatitis in CKD Patients Undergoing ERCP: A Comprehensive National Analysis

Pancreatoduodenectomy Within 2 Weeks after Endoscopic Retrograde Cholangio-Pancreatography Increases the Risk of Organ/space Surgical Site Infections: a 5-Year Retrospective Cohort Study in a High-Volume Centre

S1589 Patients With Cystic Fibrosis Do Not Have an Increased Risk of Adverse Events After Endoscopic Retrograde Cholangiopancreatography: A Propensity-Matched Analysis

Preventive Measures and Risk Factors for Post-ERCP Pancreatitis: A Systematic Review and Individual Patient Data Meta-Analysis

Clinical Profiles and Outcomes of Patients Undergoing Endoscopic Retrograde Cholangiopancreatography in a Tertiary Care Center

Pharmacological prophylaxis versus pancreatic duct stenting plus pharmacological prophylaxis for prevention of post-ERCP pancreatitis in high risk patients: a randomized trial

S1529 Impact of High-Volume Crystalloid Infusion and Indomethacin Prophylaxis on Post-ERCP Pancreatitis Rates in Patients With Difficult Cannulation

Risk Factors for Post Endoscopic Retrograde Cholangio Pancreatography(ERCP) Pancreatitis (PEP) and Efficacy of Octreotide in its Prevention

Follow-up to determine unplanned hospitalization and complications after endoscopic retrograde cholangiopancreatography

S1535 Post-Endoscopic Retrograde Cholangiopancreatography (ERCP) Complications in Patients with Liver Cirrhosis